Previous 10 | Next 10 |
IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2022 /PRNewsw...
IDEAYA Biosciences Announces Corporate and Portfolio Update for J.P. Morgan 40th Annual Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 10, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision ...
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 5, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a s...
IDEAYA Biosciences Appoints Dr. Frank McCormick as Chair of Scientific Advisory Board PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology com...
IDEAYA Biosciences to Participate in Investor Conferences in January 2022 PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company commit...
Ideaya Biosciences (NASDAQ:IDYA) provides a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients. Uveal melanoma is the most common intraocular malignancy and arises from melanocy...
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma - 100% Disease Control Rate (DCR): 16 of 16 evaluable patients demonstrate tumor shrinkage - 31% Overall Resp...
IDEAYA Biosciences to Participate in Investor Conferences in December 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company comm...
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 29, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: ...
IDEAYA Biosciences (NASDAQ:IDYA): Q3 GAAP EPS of -$0.31 beats by $0.01. Revenue of $8.97M (-0.2% Y/Y) beats by $0.42M. Press Release For further details see: IDEAYA Biosciences EPS beats by $0.01, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...